Literature DB >> 28977486

Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.

Yin-Kai Chao1, Wen-Yu Chuang2, Chi-Ju Yeh2, Hsien-Kun Chang3, Chen-Kan Tseng4.   

Abstract

OBJECTIVES: Recent advances in neoadjuvant chemoradiotherapy (nCRT) have significantly increased the rates of pathological complete response achieved by patients with oesophageal cancer. Consequently, a watchful waiting strategy based on 'active endoscopic surveillance and surgery as needed' has been proposed for cases without clinical evidence of disease after neoadjuvant chemoradiotherapy. Here, we investigated whether endoscopic surveillance is a reliable tool for the detection of the initially unidentified residual cancer in this patient group.
METHODS: We performed a careful pathological re-review of all cases with oesophageal squamous cell carcinoma, who attained a clinical complete response, despite showing a pathological non-complete response. The detailed anatomical locations of such unidentified malignancies were investigated in each patient to determine the prevalence of cancer involvement for each oesophageal layer.
RESULTS: Among the 73 patients with clinical complete response, 46 (63%) patients were found to have pathological non-complete response. The majority (89.1%; n = 41) of patients had evidence of residual cancer in the oesophagus, whereas only 5 (10.9%) patients had T0N+ disease. However, a high percentage (39.1%; n = 16) of patients had no detectable cancer in the mucosa and 9 of them also had no detectable cancer in sub-mucosal layer, ultimately hampering their detection via endoscopic biopsy.
CONCLUSIONS: Nearly 40% of patients with oesophageal squamous cell carcinoma who attained clinical complete response but showed a pathological non-complete response had residual cancer hidden underneath a cancer-free mucosa layer.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Clinical complete response; Neoadjuvant chemoradiotherapy; Oesophageal cancer; Residual cancer; Squamous cell carcinoma

Mesh:

Year:  2018        PMID: 28977486     DOI: 10.1093/ejcts/ezx261

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.

Authors:  Berend Jan van der Wilk; Ben M Eyck; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot
Journal:  Dig Surg       Date:  2018-09-18       Impact factor: 2.588

2.  A validated nomogram integrating hematological indicators to predict response to neoadjuvant therapy in esophageal squamous cell carcinoma patients.

Authors:  Sichao Wang; Zihao Zhou; Dan Tian; Shujie Huang; Ce Wang; Zhen Gao; Xiaosong Ben; Jiming Tang; Liang Xie; Haiyu Zhou; Dongkun Zhang; Ruiqing Shi; Cheng Deng; Weitao Zhuang; Yu Ding; Guibin Qiao
Journal:  Ann Transl Med       Date:  2021-04

3.  Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.

Authors:  Xiaobin Zhang; Ben M Eyck; Yang Yang; Jun Liu; Yin-Kai Chao; Ming-Mo Hou; Tsung-Min Hung; Qingsong Pang; Zhen-Tao Yu; Hongjing Jiang; Simon Law; Ian Wong; Ka-On Lam; Berend J van der Wilk; Ate van der Gaast; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot; Zhigang Li
Journal:  BMC Cancer       Date:  2020-03-06       Impact factor: 4.430

4.  Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.

Authors:  B J van der Wilk; B M Eyck; M Doukas; M C W Spaander; E J Schoon; K K Krishnadath; L E Oostenbrug; S M Lagarde; B P L Wijnhoven; L H J Looijenga; K Biermann; J J B van Lanschot
Journal:  Br J Surg       Date:  2020-08-05       Impact factor: 6.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.